GlaxoSmithKline has announced more data making the case for its multiple myeloma antibody-drug conjugate GSK2857916, confirming that almost two thirds of patients responded to the drug afte
Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
UK artificial intelligence (AI) drug discovery company Exscientia has agreed a three year drug discovery deal with Celgene, focusing on finding new cancer and autoimmune drugs.
AbbVie and Roche have stopped recruiting patients for all multiple myeloma trials involving the drug venetoclax after a higher proportion of deaths was observed in patients receiving it tha
Roche’s Tecentriq (atezolizumab) cancer immunotherapy has gained a new indication in the US, after the FDA granted it a licence in a difficult to treat form of lung cancer in combination wi
Shares in Celgene ticked up yesterday after a let-off in a US court case challenging the patents on its multi-billion dollar cancer drug Revlimid, a decision that could ease shareholder ten